ExonHit Therapeutics (Paris:ALEHT) (Alternext: ALEHT) today announced that it has obtained the "Innovative Company" accreditation from OSEO (the French state innovation agency), in recognition of the company's cutting-edge innovations in its target sectors. The accreditation means that French innovation-focused mutual funds (FCPI) can now make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.
"We are delighted to have received this OSEO accreditation, which emphasizes our particularly innovative strategy in genomic profiling that we apply both in therapeutics and in diagnostics. We are continuing our investments and research efforts with a view to offering personalized medical solutions in Alzheimer's disease and cancer - both of which are major public health issues", commented Loïc Maurel MD, President of the Management Board at ExonHit Therapeutics.
This new milestone forms part of ExonHit's unrelenting commitment to innovation in the fields of neurodegenerative diseases and oncology. It follows on from last December's launch of AclarusDx™ the company's first research-use-only molecular test for Alzheimer's disease.